Cancer Therapeutic Procedure
Aizen Therapeutics Unveils AI-Driven ‘Mirror Peptide’ Platform to Revolutionize Drug Development
Aizen Therapeutics, Caltech spinout, AI-driven platform, mirror peptides, drug development, biologic medicine, cancer treatment
BeiGene Secures Long-Term Protection for BRUKINSA with Patent Settlement Until 2037
BeiGene, BRUKINSA, patent settlement, MSN Pharmaceuticals, generic competition, market exclusivity, BTK inhibitor, cancer treatment
Novartis and Ratio Therapeutics Ink $745M Radiopharmaceutical Deal
Novartis, Ratio Therapeutics, radiopharmaceutical pact, $745M deal, cancer treatment
Adaptimmune Prepares for Next FDA Submission Following Success in Pivotal Sarcoma Study
Adaptimmune, FDA submission, sarcoma study, afami-cel, lete-cel, cell therapy, synovial sarcoma, cancer treatment
BioNTech Acquires Biotheus for $800M to Enhance Oncology Strategy with Promising Bispecific Antibody
BioNTech, Biotheus, oncology, bispecific antibody, BNT327/PM8002, PD-L1, VEGF-A, cancer treatment, acquisition
Daiichi Sankyo and Alteogen Collaborate on Subcutaneous Enhertu Development in $300M Licensing Agreement
Daiichi Sankyo, Alteogen, subcutaneous Enhertu, $300M licensing deal, human hyaluronidase, cancer treatment
Arcus Biosciences Reveals Positive Data from Terminated TIGIT Combo Trial, Supporting Future Development
Arcus Biosciences, TIGIT combo, domvanalimab, zimberelimab, cancer treatment, clinical trials
Advancements in Bispecific Antibody Therapies: Recent Deals and Clinical Data on VEGF-Targeting Agents
Bispecific antibodies, VEGF, neovascular age-related macular degeneration (nAMD), cancer therapy, clinical trials, royalty agreements.
A Decade of Progress: Immuno-oncology on the Cusp of a New Era
Immuno-oncology, checkpoint inhibitors, bispecific antibodies, cancer treatment, immunotherapy, cancer research, future of cancer care.
CARsgen and Galapagos Resume CAR-T Trials Without Restrictions
CAR-T trials, CARsgen, Galapagos, cancer treatment, clinical trials